Emily Grist

ERG Orchestrates a Dedifferentiation–Senescence–Inflammation Triad in Prostate Cancer

Francesca Lorenzin, Giulia Fracassi, Federico Vannuccini, Mazlina Ismail et autres

it, gb, be, us, il (code pays fourni par la source)

Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.

Christopher Sweeney, J Proudfoot, Simranjeet Kaur, Darby Thompson et autres

au, us, gb (code pays fourni par la source)

Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).

Anis Hamid, Monica Guilhaus, Arun Azad, Jacqueline Rehn et autres

us, au, gb, ca (code pays fourni par la source)

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer

Larissa Mendes, Peter F Dutey-Magni, Emily Grist, Ashwin Sachdeva et autres

gb, au (code pays fourni par la source)

Induction and the early career substitute teacher workforce: problems, confusion and possible solutions

Anna V. Shaw Sullivan, Emily Grist, Michele Simons, Neil Tippett et autres

au (code pays fourni par la source)

The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test

Emily Grist, Christopher J. Sweeney, Gerhardt Attard

gb, au (code pays fourni par la source)

Precariously employed early career teachers and induction policies: a critical policy study

Emily Rowe, Anna Sullivan, Neil Tippett, Michele Simons et autres

au (code pays fourni par la source)

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

Emily Grist, Peter Dutey‐Magni, Marina Parry, Larissa Mendes et autres

gb, us, ch, fi, au (code pays fourni par la source)

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Silke Gillessen, Laura Murphy, Nicholas D James, Ashwin Sachdeva et autres

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

Silke Gillessen, L.R. Murphy, Nicholas D. James, Ashwin Sachdeva et autres

ch, gb (code pays fourni par la source)

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol

Charles Parker, Larissa Mendes, Vinnie Y.T. Liu, Emily Grist et autres

gb, us, ch (code pays fourni par la source)

Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.

Charles Thomas Parker, Vinnie YT Liu, Larissa Mendes, Emily Grist et autres

gb, ch, us (code pays fourni par la source)